Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WELLCOVORIN vs SOMA COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Folinic acid (leucovorin) is a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, providing cofactors for nucleotide synthesis and reversing the effects of folate antagonists such as methotrexate.
Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Rescue therapy after high-dose methotrexate therapy in osteosarcoma,Treatment of advanced colorectal cancer in combination with fluorouracil (off-label),To diminish toxicity and counteract effects of folic acid antagonists (e.g., trimethoprim, pyrimethamine) in certain infections
Relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: management of muscle spasms, tension headaches
WELLCOVORIN (levoleucovorin) is administered intravenously or intramuscularly at a dose of 7.5 mg (approximately 0.1 mg/kg) every 6 hours for 10 doses starting 24 hours after the end of methotrexate infusion. Alternatively, 15 mg orally every 6 hours for 10 doses, starting 24 hours after methotrexate infusion.
1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.
The terminal elimination half-life of folinic acid (active reduced folate) is approximately 6-7 hours in patients with normal renal function. The pharmacologically active metabolite, 5-methyltetrahydrofolate, has a longer half-life of about 10-12 hours. In renal impairment, half-life may be prolonged.
Carisoprodol: approximately 2-4 hours in adults with normal renal function. Meprobamate: approximately 10-12 hours. The prolonged half-life of meprobamate contributes to accumulation with repeated dosing, especially in elderly or renally impaired patients, leading to increased risk of sedation and dependence.
Folinic acid is metabolized via reduction and methylation to active folate forms (e.g., 5-methyltetrahydrofolate) in the liver and other tissues. Involves dihydrofolate reductase and other folate-metabolizing enzymes.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite); aspirin is hydrolyzed to salicylic acid via esterases in the liver and plasma.
Primarily renal excretion as unchanged drug and metabolites; about 80-90% of a dose is excreted in urine within 24 hours, with approximately 50-70% as unchanged folinic acid and the remainder as 5-methyltetrahydrofolate and other metabolites. Fecal excretion accounts for <10%.
Carisoprodol and its active metabolite meprobamate are primarily excreted renally. Approximately 60% of a dose is eliminated as unchanged carisoprodol and meprobamate in urine, with the remainder as various hydroxylated metabolites. Less than 1% is eliminated in feces. Meprobamate undergoes hepatic metabolism, and about 10-20% is excreted unchanged in urine.
Approximately 15% bound to plasma proteins, mainly albumin. Binding is not extensive.
Carisoprodol: approximately 60% bound to plasma proteins, primarily albumin. Meprobamate: approximately 15-25% bound to plasma proteins.
Volume of distribution is approximately 0.5-0.6 L/kg, indicating distribution into total body water and some tissue binding. It crosses the blood-brain barrier poorly.
Carisoprodol: Vd approximately 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding. Meprobamate: Vd about 0.7 L/kg.
Oral bioavailability is variable: approximately 25-30% for the active isomer (l-folinic acid) due to first-pass metabolism; the racemic mixture (d,l-folinic acid) has a lower absolute bioavailability of about 30% for the active component. Intravenous and intramuscular routes provide 100% bioavailability.
Oral: Carisoprodol is well absorbed with bioavailability >90%. The absorption rate may be slightly reduced with food, but extent is not significantly affected.
No specific GFR-based dose modifications are provided in the prescribing information. However, levoleucovorin is renally eliminated, and caution is advised in patients with renal impairment. For severe renal impairment (Cr Cl < 10 m L/min), consider dose reduction or extended interval. Monitor methotrexate levels and adjust leucovorin dose accordingly.
Cr Cl <30 m L/min: avoid use due to aspirin component; Cr Cl 30-50 m L/min: reduce dose or extend interval; monitor for carisoprodol accumulation.
No specific dose adjustments are recommended for hepatic impairment based on Child-Pugh class. However, caution is advised in patients with significant hepatic dysfunction due to potential altered folate metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
WELLCOVORIN is not FDA approved for pediatric use. However, in pediatric patients, levoleucovorin is sometimes used at a dose of 10 mg/m² (or 0.2 mg/kg) every 6 hours for 5-7 doses, starting 24 hours after methotrexate infusion, adjusted based on methotrexate levels. Dosing should be individualized based on clinical response and methotrexate concentration.
Not recommended for children under 12 years; safety and efficacy not established.
No specific geriatric dose adjustments are recommended. Due to age-related decline in renal function, monitor renal function and methotrexate levels closely, and consider dose adjustment based on creatinine clearance.
Initiate at lowest dose (1 tablet); avoid use in patients with Cr Cl <30 m L/min; monitor for CNS depression and bleeding risk.
No FDA black box warning.
No FDA black box warning.
May mask pernicious anemia and other megaloblastic anemias due to vitamin B12 deficiency; caution in patients with renal impairment; hypersensitivity reactions; gastrointestinal toxicity with 5-FU combination.
Dependence and withdrawal: Carisoprodol can cause dependence, abuse, and withdrawal symptoms after prolonged use,Sedation: May impair mental or physical abilities; caution with driving or operating machinery,Bleeding risk: Aspirin component increases risk of bleeding, especially with alcohol, anticoagulants, or existing bleeding disorders,Hypersensitivity: Allergic reactions including anaphylaxis can occur
History of severe hypersensitivity to folinic acid; pernicious anemia or other megaloblastic anemias secondary to vitamin B12 deficiency.
History of acute intermittent porphyria,Hypersensitivity to carisoprodol, meprobamate, aspirin, or any component,Severe hepatic or renal impairment,Gastrointestinal bleeding or peptic ulcer disease (active),Children with viral infections (Reye's syndrome risk),Third trimester of pregnancy (aspirin component)
No significant food interactions have been reported. However, maintain adequate hydration and avoid alcohol due to potential hepatotoxicity. No specific dietary restrictions are required.
Avoid alcohol. Aspirin may cause gastrointestinal irritation; take with food or a full glass of water to reduce risk. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity.
WELLCOVORIN (levoleucovorin) is a folate analog. Folate is essential for fetal development. Wellcovorin is the active enantiomer of leucovorin, which is used to counteract folic acid antagonists. Available data do not indicate an increased risk of major birth defects with therapeutic doses. However, high-dose methotrexate therapy (which Wellcovorin is used to rescue from) is teratogenic. During first trimester, folate supplementation is protective against neural tube defects. During second and third trimester, folate requirements increase. No specific fetal risks are known from Wellcovorin alone. However, the underlying condition requiring treatment may pose risks.
Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin component (if present in compound) is associated with increased risk of neural tube defects and fetal hemorrhage if used in third trimester. Avoid use during pregnancy unless benefit outweighs risk.
Levoleucovorin is excreted into human milk. The M/P ratio is not established. Due to low molecular weight, excretion is expected. Exposure to the breastfed infant is likely low. Caution is advised. Use only if clearly needed.
Carisoprodol and its active metabolite meprobamate are excreted in breast milk. M/P ratio not well established. Concentrations may reach clinical significance. Potential for infant sedation, hypotonia, or withdrawal. Avoid breastfeeding while on this medication.
Pregnancy increases folate clearance. Dose may need adjustment to maintain adequate serum folate levels, especially in high-dose methotrexate rescue. Monitor serum folate and adjust dose accordingly. Specific dose changes are not established; clinical judgment and monitoring are required.
No established dosing adjustments for pregnancy. Due to increased renal clearance during pregnancy, consider that standard doses may be less effective. However, lack of safety data generally contraindicates use. If absolutely necessary, use lowest effective dose for shortest duration.
WELLCOVORIN (levoleucovorin) is the active l-isomer of leucovorin; it does not require metabolic activation and is preferred in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. It is used to reduce the toxicity of methotrexate (MTX) and to enhance the efficacy of fluorouracil (5-FU). When used for MTX rescue, initiate 24 hours after start of MTX infusion; monitor serum MTX levels, creatinine, and urine p H. Rescue dose and duration depend on MTX levels; continue until MTX level < 0.05 μmol/L. For 5-FU modulation, administer immediately before or simultaneously with 5-FU; do not use with irinotecan due to increased diarrhea risk.
Soma Compound contains carisoprodol (a centrally acting muscle relaxant) and aspirin (an NSAID). Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with a history of substance abuse, porphyria, or G6PD deficiency. Monitor for signs of CNS depression, especially when combined with alcohol or other sedatives. Aspirin increases bleeding risk; avoid in patients with bleeding disorders or those on anticoagulants. Do not use in children or adolescents with viral infections due to risk of Reye's syndrome.
Take this medication exactly as prescribed; do not change the dose or frequency without consulting your doctor.,This drug may be given as an injection or as an oral tablet; follow the instructions for the specific formulation you receive.,If you miss a dose, contact your healthcare provider; do not double the next dose.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing) or severe gastrointestinal symptoms (severe diarrhea, vomiting, abdominal pain) immediately.,Drink plenty of fluids to stay hydrated, especially during chemotherapy treatment.,Avoid alcohol while taking this medication as it may increase the risk of liver toxicity.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Take exactly as prescribed; do not increase dose or frequency.,Do not drive or operate heavy machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report any signs of bleeding (bruising, black stools, blood in urine) or allergic reactions (rash, swelling, difficulty breathing).,Do not use in children or teenagers with chickenpox or flu symptoms due to risk of Reye's syndrome.,This medication may be habit-forming; do not stop abruptly without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Common clinical questions about WELLCOVORIN vs SOMA COMPOUND, answered by our medical review team.
WELLCOVORIN is a Folic Acid Derivative that works by Folinic acid (leucovorin) is a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, providing cofactors for nucleotide synthesis and reversing the effects of folate antagonists such as methotrexate.. SOMA COMPOUND is a Skeletal Muscle Relaxant Combination that works by Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WELLCOVORIN and SOMA COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WELLCOVORIN is: WELLCOVORIN (levoleucovorin) is administered intravenously or intramuscularly at a dose of 7.5 mg (approximately 0.1 mg/kg) every 6 hours for 10 doses starting 24 hours after the end of methotrexate infusion. Alternatively, 15 mg orally every 6 hours for 10 doses, starting 24 hours after methotrexate infusion.. The standard adult dose of SOMA COMPOUND is: 1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WELLCOVORIN and SOMA COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WELLCOVORIN is classified as Category C. WELLCOVORIN (levoleucovorin) is a folate analog. Folate is essential for fetal development. Wellcovorin is the active enantiomer of leucovorin, which is used to counteract folic ac. SOMA COMPOUND is classified as Category C. Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin com. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.